机构投资者根据高收入和55.61美元的股票价格调整了Novo Nordisk的股权。 Institutional investors adjusted stakes in Novo Nordisk amid strong earnings and a $55.61 stock price.

第二季度,机构投资者在Novo Nordisk A/S(NVO)的股份发生了显著变化,Smith Chas P & Associates PA Cpas公司增加了143.6%,Capital Insight Partners LLC将其持有量减少了8.5%。 Institutional investors made notable changes to their stakes in Novo Nordisk A/S (NVO) during the second quarter, with Smith Chas P & Associates PA Cpas increasing its position by 143.6% and Capital Insight Partners LLC reducing its holding by 8.5%. 该公司报告第二季度收入为每股0.97美元,超过估计数4美元,收入为116.9亿美元。 The company reported second-quarter earnings of $0.97 per share, surpassing estimates by $0.04, with revenue of $11.69 billion. 新诺迪斯(Novo Nordisk)是糖尿病、肥胖症护理和罕见疾病治疗领域的全球领先者,市场上限为2 483亿美元,分析家的一致“坚持”评级为75-81美元,目标价格约为75-81美元。 Novo Nordisk, a global leader in diabetes, obesity care, and rare disease treatments, has a market cap of $248.3 billion and a consensus "Hold" rating from analysts, with a target price around $75–81. 股票交易额为55.61美元,P/E比率为15.28美元,最近每股半年支付0.4119美元的红利。 The stock trades at $55.61, has a P/E ratio of 15.28, and recently paid a semi-annual dividend of $0.4119 per share.